APA (7th ed.) Citation

Leypoldt, L., Gavriatopoulou, M., Besemer, B., Salwender, H., Raab, M., Nogai, A., . . . Weisel, K. C. (2023). Daratumumab, Bortezomib, and Dexamethasone for treatment of patients with relapsed or refractory multiple myeloma and severe renal impairment: Results from the phase 2 GMMG-DANTE trial. Cancers, 15(18), . https://doi.org/10.3390/cancers15184667

Chicago Style (17th ed.) Citation

Leypoldt, Lisa, et al. "Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial." Cancers 15, no. 18 (2023). https://doi.org/10.3390/cancers15184667.

MLA (9th ed.) Citation

Leypoldt, Lisa, et al. "Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial." Cancers, vol. 15, no. 18, 2023, https://doi.org/10.3390/cancers15184667.